Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 172

The DOI matches its Crossref record; 14 of the 14 references it cites were found in a registry or an index.

Development of a highly sensitive liquid biopsy platform to detect clinically-relevant cancer mutations at low allele fractions in cell-free DNA

Open access
Gale, Davina, Lawson, Andrew R. J., Howarth, Karen, Madi, Mikidache, Durham, Bradley, Smalley, Sarah, Calaway, John, Blais, Shannon, Jones, Greg, Clark, James, Dimitrov, Peter, Pugh, Michelle, Woodhouse, Samuel, Epstein, Michael, Fernandez-Gonzalez, Ana, Whale, Alexandra S., Huggett, Jim F., Foy, Carole A., Jones, Gerwyn M., Raveh-Amit, Hadas, Schmitt, Karin, Devonshire, Alison, Green, Emma, Forshew, Tim, Plagnol, Vincent, Rosenfeld, Nitzan·2018·PLOS ONE

Abstract

INTRODUCTION: Detection and monitoring of circulating tumor DNA (ctDNA) is rapidly becoming a diagnostic, prognostic and predictive tool in cancer patient care. A growing number of gene targets have been identified as diagnostic or actionable, requiring the development of reliable technology that provides analysis of multiple genes in parallel. We have developed the InVision™ liquid biopsy platform which utilizes enhanced TAm-Seq™ (eTAm-Seq™) technology, an amplicon-based next generation sequencing method for the identification of clinically-relevant somatic alterations at low frequency in ctDNA across a panel of 35 cancer-related genes. MATERIALS AND METHODS: We present analytical validation of the eTAm-Seq technology across two laboratories to determine the reproducibility of mutation identification. We assess the quantitative performance of eTAm-Seq technology for analysis of single nucleotide variants in clinically-relevant genes as compared to digital PCR (dPCR), using both established DNA standards and novel full-process control material. RESULTS: The assay detected mutant alleles down to 0.02% AF, with high per-base specificity of 99.9997%. Across two laboratories, analysis of samples with optimal amount of DNA detected 94% mutations at 0.25%-0.33% allele fraction (AF), with 90% of mutations detected for samples with lower amounts of input DNA. CONCLUSIONS: These studies demonstrate that eTAm-Seq technology is a robust and reproducible technology for the identification and quantification of somatic mutations in circulating tumor DNA, and support its use in clinical applications for precision medicine.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1371/journal.pone.0194630

Cites

14 of 14 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 14 references

Cited by

See all 172

Metadata

Authors
Gale, D., Lawson, A. R. J., Howarth, K., Madi, M., Durham, B., Smalley, S., Calaway, J., Blais, S., Jones, G., Clark, J., Dimitrov, P., Pugh, M., Woodhouse, S., Epstein, M., Fernandez-Gonzalez, A., Whale, A. S., Huggett, J. F., Foy, C. A., Jones, G. M., Raveh-Amit, H., Schmitt, K., Devonshire, A., Green, E., Forshew, T., Plagnol, V., & Rosenfeld, N.
Venue
PLOS ONE
Published
2018-03-16
Volume
13
Issue
3
Pages
e0194630
ISSN
1932-6203 (ISSN-L)
OpenAlex
W2790726106
Cited by
172
References
14
FWCI
4.81
Type
journal article
Language
en
Open access
gold

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Development of a highly sensitive liquid biopsy platform to detect clinically-relevant cancer mutations at low allele fractions in cell-free DNA. https://app.cochat.ai/papers/10.1371/journal.pone.0194630
The paper
Gale, D., Lawson, A. R. J., Howarth, K., Madi, M., Durham, B., Smalley, S., Calaway, J., Blais, S., Jones, G., Clark, J., Dimitrov, P., Pugh, M., Woodhouse, S., Epstein, M., Fernandez-Gonzalez, A., Whale, A. S., Huggett, J. F., Foy, C. A., Jones, G. M., . . . Rosenfeld, N. (2018). Development of a highly sensitive liquid biopsy platform to detect clinically-relevant cancer mutations at low allele fractions in cell-free DNA. PLOS ONE. https://doi.org/10.1371/journal.pone.0194630

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.